CUTANEOUS MELANOMA
Clinical trials for CUTANEOUS MELANOMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS MELANOMA trials appear
Sign up with your email to follow new studies for CUTANEOUS MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial targets Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests the safety of a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or are hard to treat. The study involves 41 participants and will look at side effects and the right dose. It is not expected to …
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
Tailor-Made vaccine takes on tough melanoma
Disease control OngoingThis early-phase study tested a personalized vaccine (NeoVax) made from each patient's unique tumor mutations, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 11 people with advanced melanoma that could not be removed by surgery. The main goal was to check sa…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-stage study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, skin, kidney, and others. The main goal is to find the safest dose and understand side effects. About 126 participants will be enrolled to see if the tre…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New drug before surgery may stop melanoma from coming back
Disease control OngoingThis study tests if giving the drug atezolizumab before surgery is safe for people with high-risk melanoma that hasn't spread. About 20 adults will receive two doses before their tumor is removed. The goal is to see if this approach can lower the chance of the cancer returning wi…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
Sweat before shots: exercise may boost cancer immunotherapy
Disease control OngoingThis early-phase study tests whether 30 minutes of moderate exercise (like cycling or walking) right before standard immunotherapy can improve how well the treatment works against certain skin cancers. About 22 adults with melanoma, squamous cell carcinoma, or Merkel cell carcino…
Matched conditions: CUTANEOUS MELANOMA
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Could one year of treatment be enough for advanced melanoma?
Disease control OngoingThis study tests whether giving the immunotherapy drug pembrolizumab for one year instead of the usual two years is just as effective for people with advanced melanoma that has spread. The trial involves 29 participants in Brazil's public health system. Researchers will track how…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo therapy aims to shrink hard-to-treat cancers
Disease control OngoingThis study tests an experimental drug called RP1, alone or with the immunotherapy nivolumab, in people with advanced solid tumors like melanoma, lung cancer, and certain skin cancers. The goal is to see if the combination is safe and can shrink tumors. About 340 adults with tumor…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New hope for tough melanoma: Dual-Drug attack shows promise
Disease control OngoingThis study tests a new drug called acasunlimab, given alone or with pembrolizumab, in adults with advanced melanoma that got worse after standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer. Participants receive active treatment and are monitore…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
Walk before treatment: could a short workout boost cancer therapy?
Symptom relief OngoingThis small pilot study tests whether a short exercise session on the same day as immunotherapy can help patients with skin cancers like melanoma. Twelve adults scheduled for their first immunotherapy will walk for 20-30 minutes before treatment. The goal is to see if this is feas…
Matched conditions: CUTANEOUS MELANOMA
Phase: NA • Sponsor: AdventHealth Translational Research Institute • Aim: Symptom relief
Last updated May 17, 2026 03:11 UTC
-
Tissue collection study aims to build smarter cancer test
Knowledge-focused OngoingThis study collects tumor tissue from about 416 people with various advanced cancers to develop and train a new diagnostic platform called Elephas. The goal is to see how accurately the platform can predict whether a patient will respond to immunotherapy, compared to standard met…
Matched conditions: CUTANEOUS MELANOMA
Sponsor: Elephas • Aim: Knowledge-focused
Last updated May 17, 2026 03:08 UTC